TIGIT Blockade Reshapes the Tumor Microenvironment Based on the Single-cell RNA-Sequencing Analysis

Area of Science:

• Immunology
• Cancer Biology
• Single-cell Sequencing

Background:

• Immune checkpoint blockade therapy is a cornerstone in cancer treatment.
• TIGIT (T cell immunoglobulin and ITIM domain) is a key target in tumor immunotherapy.
• Understanding the immune microenvironment changes after TIGIT blockade is crucial.

Purpose of the Study:

• To investigate the alterations in the immune microenvironment following TIGIT blockade therapy.
• To elucidate the cellular and molecular mechanisms underlying anti-TIGIT therapy's efficacy.

Main Methods:

• Single-cell RNA sequencing was performed on mouse models before and after anti-TIGIT therapy.
• Analysis focused on TIGIT expression patterns and immune cell responses.

Main Results:

• TIGIT is primarily expressed on T cells and natural killer (NK) cells.
• Anti-TIGIT therapy suppressed regulatory T cells (Tregs) by downregulating Foxp3 and immunosuppressive cytokines.
• TIGIT blockade enhanced NK cell activation and numbers, promoted dendritic cell (cDC1) maturation, and boosted CD8+ T cell anti-tumor activity via TCR signaling.

Conclusions:

• TIGIT blockade therapy significantly reshapes the tumor immune microenvironment.
• The therapy enhances anti-tumor immunity by modulating T cells, NK cells, and dendritic cells.
• Targeting TIGIT presents a promising strategy for future cancer immunotherapy.